More men with breast cancer are opting for double mastectomy

NewsGuard 100/100 Score

The number of men with invasive cancer in one breast who undergo surgery to remove both breasts is on the rise, according to a new report published in JAMA Surgery.

Surgery Team

The report, written by researchers from the American Cancer Society and the Dana-Farber Cancer Institute, is the first to establish this trend, which mirrors a rise in the amount of U.S women also having the surgery for unilateral breast cancer over the last 20 years. However, researchers say there is a lack of evidence to support any survival benefit as a result of having both the affected and unaffected breasts removed.

Lead author of the study Ahmedin Jemal, American Cancer Society, said:

The increase in the rate of this costly, serious procedure with no evidence of survival benefit comes, paradoxically, at a time of greater emphasis on quality and value in cancer care.”

Previous studies have shown a significant increase in the number of contralateral prophylactic mastectomy (CPM) procedures to remove both breasts in cases where women have invasive cancer in one breast. In 1998, about 2.2% of these women underwent the surgery, but this figure rose to 11% in 2011. However, it is unknown whether the use of CPM to treat male breast cancer, which accounts for around 1% of all breast cancer cases, is also increasing.

To explore whether this is the case, Jemal and colleagues looked into the treatment received by 6,332 men who underwent surgery for unilateral invasive breast cancer between 2004 and 2011. The team used nationwide data from the North American Association of Central Cancer Registries to examine the temporal trends in and factors associated with the use of CPM among the study population.

The results showed that the rates of CPM almost doubled between 2004 and 2011, from 3.0% to 5.6%. Further analysis showed that the sociodemographic factors associated with the increase were being white, younger age and having private insurance – the same factors that are linked to an increased use of CPM among women.

Jemal concludes:

Health care providers should be aware that the increase we’ve seen in removal of the unaffected breast is not limited to women. Doctors should carefully discuss with their male patients the benefits, harms, and costs of this surgery to help patients make informed decisions about their treatments,”

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2019, June 19). More men with breast cancer are opting for double mastectomy. News-Medical. Retrieved on April 25, 2024 from https://www.news-medical.net/news/20150903/More-men-with-breast-cancer-are-opting-for-double-mastectomy.aspx.

  • MLA

    Robertson, Sally. "More men with breast cancer are opting for double mastectomy". News-Medical. 25 April 2024. <https://www.news-medical.net/news/20150903/More-men-with-breast-cancer-are-opting-for-double-mastectomy.aspx>.

  • Chicago

    Robertson, Sally. "More men with breast cancer are opting for double mastectomy". News-Medical. https://www.news-medical.net/news/20150903/More-men-with-breast-cancer-are-opting-for-double-mastectomy.aspx. (accessed April 25, 2024).

  • Harvard

    Robertson, Sally. 2019. More men with breast cancer are opting for double mastectomy. News-Medical, viewed 25 April 2024, https://www.news-medical.net/news/20150903/More-men-with-breast-cancer-are-opting-for-double-mastectomy.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases